Last reviewed · How we verify
NCT06707727
Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis
trial in Myasthaenia Gravis in 100 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2025
Quick facts
| Lead sponsor | First Affiliated Hospital of Chongqing Medical University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 July 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across China |
Conditions studied
- Myasthaenia Gravis — all drugs for Myasthaenia Gravis →
Sponsor
First Affiliated Hospital of Chongqing Medical University
Who can join
Eligibility, any sex, with Myasthaenia Gravis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about the characteristics and prognostic outcomes of diaphragmatic ultrasound in myasthenia gravis. The main question it aims to answer is: Does diaphragmatic ultrasound predict prognosis of myasthenia gravis in six months? Participants diagnosed as myasthenia gravis will take the diaphragm ultrasound examinations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06707727
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myasthaenia Gravis
Currently open trials in the same condition.
- NCT06799247 — Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis · Phase 3 · recruiting
- NCT06765161 — Efgartigimod in IVIG Dependent Myasthenia Gravis Patients · Phase 3 · recruiting
- NCT06617741 — Myasthenia Gravis Foundation of America Global MG Patient Registry · recruiting
Other First Affiliated Hospital of Chongqing Medical University trials
Trials by the same sponsor.
- NCT07369713 — Efficacy and Safety of Accelerated Intermittent Theta-burst Stimulation (a-iTBS) in Adolescents With Depressive Disorder · NA · not yet recruiting
- NCT07499323 — Talquetamab in Patients With Refractory Generalized Myasthenia Gravis · NA · not yet recruiting
- NCT07409870 — An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture · not yet recruiting
- NCT07324473 — Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired R · Phase 2 · not yet recruiting
- NCT07203144 — Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06707727 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Chongqing Medical University
- Last refreshed: 27 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06707727.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing